Eli Lilly and Company (LLY) $1188.58
Eli Lilly trades within striking distance of its 52-week high, leaving little room for error at current levels.
52-wk High $1249.45
📌 Investment Snapshot
- Trading at 90% of 52-week range with 42.2x P/E multiple.
- Q1 2026 revenue reached $19.80B with $8.26 EPS.
- GLP-1 franchise growth remains the primary catalyst.
- Consensus target of $1240.46 implies limited 4.3% upside.
The technical setup signals caution. With the RSI at 65.5 and limited upside to the consensus price target, the risk-reward profile favors patience over immediate exposure.
| 📍 Entry Zone | $1050 or below | 🛑 Stop-Loss | $980 |
| 📋 Adjust If | A clean breakout above $1250 on high volume would invalidate the current wait thesis. | ||
The Investment Case — Why Now?
Lilly’s 3-month return of 26.7% highlights the market’s aggressive pricing of its GLP-1 franchise. This momentum reflects strong execution, yet the valuation now demands flawless quarterly performance.
The 42.2x P/E multiple prices in significant growth, leaving the stock vulnerable to any minor miss or macro shift. Investors should demand a clearer consolidation pattern before committing new capital.
🤔 Does the current P/E multiple justify the growth trajectory, or is the market pricing in perfection?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers |
📈 Price Action & Technicals
Outside VA
Sell-side Sweep at $1238.0 on 2026-07-07
The stock holds comfortably above the SMA50 at $1086, establishing a clear floor for the bulls. However, the distance to the SMA200 at $993 suggests the stock remains extended from its long-term mean.
RSI at 65.5 approaches overbought territory, signaling that the recent rally may require a breather. While the MACD remains positive, the lack of a bullish crossover warns against chasing the current price action.
Volume remains anemic at 64% of the 20-day average, indicating a lack of conviction behind the recent move. This low-volume drift often precedes a liquidity sweep to test lower support levels.
The anchored VWAP from August 2025 sits at $937, confirming a strong long-term uptrend. Yet, the recent sell-side sweeps at $1238 and $1149 reveal active institutional profit-taking near the highs.
Historically, this pattern of low-volume grinding followed by liquidity sweeps points to a potential mean reversion. We expect a test of the $1100 support zone before any sustainable breakout occurs.
🤔 With volume running well below average, are you seeing an exhaustion rally or a consolidation phase?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| LLY | Eli Lilly | 42.2x |
| NVO | Novo Nordisk | 38.5x |
| PFE | Pfizer | 14.2x |
| MRK | Merck | 16.8x |
| SPY | S&P 500 | 22.1x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $19.80B | $8.26 | +27% |
| Q4 2025 | $19.29B | $7.39 | +22% |
| Q3 2025 | $17.60B | $6.21 | +18% |
| Q2 2025 | $15.56B | $6.29 | +15% |
Free cash flow generation remains robust at $2.8B, supporting aggressive buyback activity of $2.4B in the latest quarter.
Revenue growth continues to accelerate, driven by high demand for metabolic therapies. The company maintains strong margins despite heavy R&D investment.
🚀 Growth Drivers — What Moves the Stock
- GLP-1 Market Dominance 🟡 Priced In — Continued expansion of Zepbound and Mounjaro market share.
- Pipeline Execution 🟢 Upside Surprise — Upcoming readouts for Alzheimer’s and immunology assets.
🤔 Which pipeline asset carries the most potential to move the needle beyond the current GLP-1 success?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Lilly Endowment, Inc | 91,896 |
| Blackrock Inc. | 66,380 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| YUFFA ILYA | Officer | 2026-06-10 | Sale | 2500 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 1.1% | 2.7 |
⚠ Key Risk Factors
~$50B impact
~$100B impact
~$75B impact
~$40B impact
🤔 How should investors weigh the risk of legislative pricing pressure against the company’s current growth rate?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $1500.00 | $1240.46 | $850.00 | 28 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| B of A Securities | Buy | $1300 | 2026-07-10 | Maintained |
| JP Morgan | Overweight | $1250 | 2026-07-07 | Maintained |
Analysts remain bullish, but the tight spread between current price and mean target suggests a period of consolidation.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Unmatched demand for metabolic franchise.
- Strong cash flow supports continued R&D and buybacks.
📊 Base Case
Stock consolidates within the $1050-$1200 range as growth normalizes.
🐻 Bear Case
- Valuation compression due to rising rates.
- Supply chain bottlenecks limit revenue upside.
🎯 Investor Action Plan — By Profile
Avoid new longs until the RSI cools below 50 or a retest of the $1100 support zone occurs.
Hold existing positions but avoid adding at current premium levels.
Maintain core exposure; wait for a deeper pullback to add to the position.
❓ Investor FAQ — People Also Ask
Q: Is Eli Lilly overvalued at 42x P/E?
The valuation is high relative to the broader market, but justified if the company maintains its current double-digit growth trajectory.
Q: What is the key support level to watch?
The $1056 level, which aligns with the Volume Profile Point of Control, serves as a critical support zone.
Q: Should I sell my shares now?
Unless your thesis has changed, holding is prudent, but consider trimming if the stock breaks below the $1080 support level.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 How has the stock moved since this analysis?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. All investments carry risk.
All active positions and their real-time performance are tracked on our Investment Log.
#LLY #EliLilly #Pharma #StockMarket #Investing #Healthcare #GLP1 #Trading